A low resting heart rate at diagnosis predicts favourable long-term outcome in pulmonary arterial and chronic thromboembolic pulmonary hypertension. A prospective observational study

Respiratory Research

Silvia Ulrich³  Rudolf Speich²  Stephan Keusch¹  Lars C Huber¹  Ivan Fauchère²  Florian F Hildenbrand¹ 

[1] Department of Heart, Vessel, Thorax, University Hospital of Zurich, Zurich, 8091, Switzerland;Department of Internal Medicine and Oncology, University Hospital of Zurich, Zurich, Switzerland;Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland

关键词: Pulmonary arterial hypertension;    Pulmonary hypertension;    Prognosis;    Heart rate;    Chronic thromboembolic pulmonary hypertension;   

Others  :  796662
DOI  :  10.1186/1465-9921-13-76

 received in 2012-03-01, accepted in 2012-07-19,  发布年份 2012

【 摘 要 】

Background

A low resting heart rate (HR) is prognostically favourable in healthy individuals and in patients with left heart disease. In this study we investigated the impact of HR at diagnosis on long-term outcome in patients with differently classified precapillary pulmonary hypertension (pPH).

Methods

pPH patients diagnosed as pulmonary arterial (PAH) or inoperable chronic thromboembolic pulmonary hypertension (CTEPH) were registered and regularly followed at our centre Baseline characteristics and events defined as either death or lung transplantation were noted. The prognostic value of HR was analysed using Kaplan Meier estimates, live tables and Cox regression.

Results

206 patients with PAH (148) and inoperable CTEPH (58) were included. The median HR was 82 bpm. pPH with a HR below 82 bpm had a significantly longer overall event-free survival (2409 vs.1332 days, p = .000). This advantage was similarly found if PAH and CTEPH were analysed separately. Although a lower HR was associated with a better hemodynamic and functional class, HR was a strong and independent prognostic marker for transplant free survival even if corrected for age, sex, hemodynamics and functional status.

Conclusion

We show that resting HR at diagnosis is a strong and independent long-term prognostic marker in PAH and CTEPH. Whether reducing HR by pharmacological agents would improve outcome in pPH has to be assessed by future trials with high attention to safety.

【 授权许可】

   
2012 Hildenbrand et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

【 参考文献 】

• [1]Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L: Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010, 376(9744):886-894.
• [2]Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM: Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010, 159(4):612-619 e613.
• [3]Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R: Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372(9641):817-821.
• [4]Heusch G: Heart rate and heart failure. Not a simple relationship. Circ J 2011, 75(2):229-236.
• [5]Bossone E, Paciocco G, Iarussi D, Agretto A, Iacono A, Gillespie BW, Rubenfire M: The prognostic role of the ECG in primary pulmonary hypertension. Chest 2002, 121(2):513-518.
• [6]Henkens IR, Van Wolferen SA, Gan CT, Boonstra A, Swenne CA, Twisk JW, Kamp O, van der Wall EE, Schalij MJ, Vonk-Noordegraaf A, et al.: Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2009, 103(10):1451-1456.
• [7]Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G: Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension. Eur Respir J 2006, 27(1):114-120.
• [8]Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al.: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S)):5S-12S.
• [9]McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al.: ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009, 53(17):1573-1619.
• [10]ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1):111-117.
• [11]Heusch G: A BEAUTIFUL lesson–ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J 2009, 30(19):2300-2301.
• [12]Borer JS, Le Heuzey JY: Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008, 15(5):461-473.
• [13]Lanza GA, Fox K, Crea F: Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol 2006, 43:1-16.
• [14]Beddhu S, Nigwekar SU, Ma X, Greene T: Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant 2009, 24(8):2482-2488.
• [15]Kapoor JR, Heidenreich PA: Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail 2010, 16(10):806-811.
• [16]Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30(20):2493-2537.
• [17]Horan LG, Flowers NC, Havelda CJ: Relation between right ventricular mass and cavity size: an analysis of 1500 human hearts. Circulation 1981, 64(1):135-138.
• [18]Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF: The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009, 135(3):794-804.
• [19]Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, et al.: Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010, 182(5):652-660.
• [20]Tongers J, Schwerdtfeger B, Klein G, Kempf T, Schaefer A, Knapp JM, Niehaus M, Korte T, Hoeper MM: Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007, 153(1):127-132.
• [21]Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344(22):1651-1658.
• [22]Reiter MJ, Reiffel JA: Importance of beta blockade in the therapy of serious ventricular arrhythmias. Am J Cardiol 1998, 82(4A):9I-19I.
• [23]Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, et al.: Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283(10):1295-1302.
• [24]Nakamura K, Fujio H: Are adrenergic receptor blockers effective or contraindicated in pulmonary arterial hypertension? Circ J 2009, 73(12):2212-2213.
• [25]Peacock A, Ross K: Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents. Thorax 2010, 65(5):454-455.